A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

  • End date
    May 20, 2023
  • participants needed
  • sponsor
    Hunan Cancer Hospital
Updated on 15 August 2021
squamous cell carcinoma
neutrophil count
adenosquamous carcinoma
tumor cells
pet/ct scan
recurrent cervical cancer
concurrent chemoradiation


In this single-arm study, patient with cervical cancer who had recurrence of the pelvic wall after surgery Abdominal aortic lymph node metastasis will be included to evaluate the efficacy and safety of camrelizumab combined with concurrent chemoradiation and subsequent maintenance therapy


The patient received neoadjuvant therapy once every three weeks for a total of seventeen cycles. From the first day of treatment, the patient will undergo concurrent chemoradiation for 5 weeks.The chemotherapy drug is cisplatin or carboplatin every week for 5 weeks. After the end of concurrent chemoradiation, the patient will continue to use camrelizumab as maintenance therapy until one year.

Condition carcinoma of the cervix, Uterine Serous Carcinoma, cervical cancer, uterine, Uterine Cancer, cervical carcinoma, cervix cancer, cancer of the cervix, carcinoma of cervix, Cervical Cancer, carcinoma of the cervix uteri, Disorders of cervix NOS
Treatment Camrelizumab, Cisplatin or Carboplatin
Clinical Study IdentifierNCT04974827
SponsorHunan Cancer Hospital
Last Modified on15 August 2021


Yes No Not Sure

Inclusion Criteria

Age 18 years old
Understand the research procedures and content, and voluntarily sign informed consent
Cervical squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma confirmed by histology or cytology
Patients diagnosed as recurrent cervical cancer on the pelvic wall by histology or cytology. If histology or cytology is not available, provide clinical diagnosis in combination with medical history, laboratory examinations and imaging examinations (such as CT, MRI, PET/CT)
According to the RECIST 1.1 standard, the subject must have at least one measurable target lesion on the pelvic wall by CT or MRI (the longest diameter 10mm lesion, or the short diameter 15mm lymph node)
CT or MRI examination or PET-CT examination showed no distant metastasis
Expected survival period 3 months
ECOG score: 0-1
Participants need to provide sufficient formalin-fixed paraffin-embedded (FFPE) specimens or sections prepared from tumor archive tissues or fresh tissues that meet the testing standards, and are willing to perform tumor tissue biopsy when needed for PD-L1 Detection. The archived tissue must be a representative tumor specimen within three years, or an unstained serial section (not less than 4 pieces) of newly cut FFPE tumor tissue within six months, and relevant pathological reports of the above specimens must be provided. The methods of obtaining fresh tissue specimens can be surgical resection and biopsy. The methods of biopsy include but are not limited to core needle biopsy, endoscopic resection or clamp biopsy (enough tumor cells must be guaranteed> 100); Fine needle aspiration and liquid-based cytology (TCT) samples are not accepted (it means that there isn't a complete tissue structure and Participants only provide cell suspension and/or cell smears); Decalcified bone metastasis tumor tissue specimens are not accepted. For patients who are PD-L1 negative in the initial archived tumor tissue samples, after obtaining the patient's consent, a biopsy can be performed during screening to provide wax blocks or sections prepared from fresh tissues to retest PD-L1 status
The investigator assesses suitability for concurrent chemoradiation
The values of laboratory tests performed during the screening period must meet the following criteria Hemoglobin (HGB) 90g/L Absolute neutrophil count (ANC) 1.5109/L Platelet (PLT) 100109/L Total bilirubin (TBIL)1.5ULN (Gilbert syndrome allows 5ULN) Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5ULN Serum creatinine (Cr) 1.5 ULN or endogenous creatinine clearance 50mL/min
Thyroid function index: free thyroxine (FT3/FT4) in the normal range
Subjects can be followed up on schedule, can communicate well with the investigator and can complete the study in accordance with the regulations of this study

Exclusion Criteria

Histological examination results are small cell (neuroendocrine) cervical cancer and mucinous adenocarcinoma
CT, MRI or PET-CT examination shows diffuse pelvic metastasis
CT, MRI or PET-CT examination shows distant metastasis (excluding retroperitoneal lymph node metastasis)
Simple vaginal recurrence
Active central nervous system (CNS) metastases, including symptomatic brain metastases,meningeal metastases or spinal cord compression, etc.Asymptomatic brain metastases can be included in the group (no progression for at least 4 weeks after radiotherapy and/or no neurological symptoms or signs after surgical resection, no need for treatment with glucocorticoids, anticonvulsants or mannitol)
Systemic chemotherapy, targeted therapy, anti-tumor biological therapy (such as tumor vaccine, cytokine or growth factor, etc.) have been performed before the study drug
The effect of major surgery or severe trauma before study medication has been eliminated within 14 days(Those who have undergone local anesthesia or percutaneous needle biopsy within 7 days and have recovered can be included in the group)
Participants received systemic corticosteroids (prednisone>10mg/day or equivalent dose) or other immunosuppressive drugs within 14 days before the study medication
A history of active and known autoimmune diseases, including but not limited to systemic lupus erythematosus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, Hashimoto's thyroiditis, etc. Except for type I diabetes, hypothyroidism that can be controlled only by hormone replacement therapy, skin diseases that do not require systemic treatment (such as vitiligo), and controlled celiac disease
Complications that need to be treated with immunosuppressive drugs, or Complications that need to be treated systemically with an immunosuppressive dose (prednisone> 10 mg/day or equivalent dose of similar drugs). In the absence of active autoimmune diseases, inhaled or topical steroids and doses> 10mg/day of prednisone or equivalent doses of similar drugs are allowed
Uncontrolled hypertension (systolic blood pressure> 140 mmHg and/or diastolic blood pressure> 90 mmHg) or pulmonary hypertension or unstable angina pectoris; myocardial infarction or bypass or stent surgery within 6 months before administration. A history of chronic heart failure that meets NYHA standards 3-4; clinically significant valvular disease; Severe arrhythmia requiring treatment, including QTc interval 470ms (calculated by Fridericia formula); left ventricular ejection fraction (LVEF) <50%;Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within 6 months before administration
Combined with other serious medical diseases, including but not limited to uncontrolled diabetes, active peptic ulcer, active bleeding, etc
Patients with active infection who need systemic treatment
Patients with previous or current active tuberculosis infection
The patient has a history of interstitial lung disease
Symptomatic and uncontrollable serous effusion such as peritoneal effusion, pleural effusion or pericardial effusion
Human immunodeficiency virus antibody (HIV-Ab) positive; patients with active syphilis infection; hepatitis C antibody (HCV-Ab) positive, and hepatitis C virus RNA quantification> the upper limit of normal value of detection unit; hepatitis B virus surface antigen (HBsAg) is positive, and hepatitis B Virus detection value> upper limit of normal value of detection unit
Adverse reactions caused by previous treatment have not recovered to grade 1 or below (CTCAE5.0) (except for hair loss and grade 2 neurotoxicity caused by chemotherapy drugs)
Previously treated with anti-PD-1 antibody, anti-PD-L1 antibody, anti-PD-L2 antibody or anti-CTLA-4 antibody (or any other antibody that acts on T cell co-stimulation or checkpoint pathway)
Radiotherapy has been performed on the area to be irradiated in the past
Have used live vaccines or attenuated vaccines within 28 days before study medication
Participants have used other investigational drug treatments or investigational devices within 30 days before the study medication
People with a history of drug abuse or drug abuse
Have a clear history of neurological or mental disorders, such as epilepsy, dementia, and poor compliance
Women who are breastfeeding and do not agree to stop breastfeeding
Patients are known to be allergic to recombinant humanized PD-1 monoclonal antibody or any of its excipients; patients are known to have a history of allergic diseases or have severe allergies
The investigator believes that the patient is not suitable for participating in this clinical research for various other reasons
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer  to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note